siRNA Targeting Mcl-1 Potentiates the Anticancer Activity of Andrographolide Nanosuspensions via Apoptosis in Breast Cancer Cells
Authors:
- Supusson PengnamSupusson Pengnam
- Purin CharoensuksaiPCPurin Charoensuksai
- Boon-Ek YingyongnarongkulBYBoon-Ek Yingyongnarongkul
- Rungnapha SaeengRSRungnapha Saeeng
- Hasan UludağHUHasan Uludağ
- Prasopchai PatrojanasophonPPPrasopchai Patrojanasophon
- Praneet OpanasopitPOPraneet Opanasopit
- Samarwadee PlianwongSPSamarwadee Plianwong
Open Access
- 3 June 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (6) , 1196
Abstract
Breast cancer is the second leading cause of cancer-related death in the US. However, recurrence is frequently found despite adjuvant therapy being available. Combination therapy with cytotoxic drugs and gene therapy is being developed to be a new promising cancer treatment strategy. Introducing substituted dithiocarbamate moieties at the C12 position of andrographolide (3nAG) could improve its anticancer selectivity in the MCF-7 breast cancer cell line. However, its hydrophobicity is one of its main drawbacks. This work successfully prepared 3nAG nanosuspension stabilized with the chitosan derivative NSC (3nAGN-NSC) to increase solubility and pharmacological effectiveness. siRNAs have emerged as a promising therapeutic alternative for interfering with particular mRNA. The 3nAGN-NSC had also induced Mcl-1 mRNA expression in MCF-7 human breast cancer cells at 8, 12, and 24 h. This indicates that, in addition to Mcl-1 silencing by siRNA (siMcl-1) in MCF-7 with substantial Mcl-1 reliance, rationally devised combination treatment may cause the death of cancer cells in breast cancer. The Fa-CI analysis showed that the combination of 3nAGN-NSC and siMcl-1 had a synergistic effect with a combination index (CI) value of 0.75 (CI < 1 indicating synergistic effects) at the fractional inhibition of Fa 0.7. The synergistic effect was validated by flow cytometry, with the induction of apoptosis as the mechanism of reduced cell viability. Our findings suggested the rational use of 3nAGN-NSC in combination with siMcl-1 to kill breast cancer cells.Keywords
Funding Information
- Fundamental Fund Research (2377371, N42A650551)
- National Research Council of Thailand (2377371, N42A650551)
This publication has 61 references indexed in Scilit:
- Autophagy-dependent EIF2AK3 activation compromises ursolic acid-induced apoptosis through upregulation of MCL1 in MCF-7 human breast cancer cellsAutophagy, 2013
- Role of the Crosstalk between Autophagy and Apoptosis in CancerJournal of Oncology, 2013
- Defining principles of combination drug mechanisms of actionProceedings of the National Academy of Sciences, 2012
- Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapyDrug Discovery Today, 2012
- Identification of genes involved in the regulation of 14-deoxy-11,12-didehydroandrographolide-induced toxicity in T-47D mammary cellsFood and Chemical Toxicology, 2012
- Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivoCancer Biology & Therapy, 2010
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay MethodCancer Research, 2010
- Advances in Breast Cancer: Pathways to Personalized MedicineClinical Cancer Research, 2008
- Benzylidene derivatives of andrographolide inhibit growth of breast and colon cancer cells in vitro by inducing G1 arrest and apoptosisBritish Journal of Pharmacology, 2008
- Andrographolide Inhibits Human Hepatoma-Derived Hep3B Cell Growth through the Activation of c-Jun N-Terminal KinasePlanta Medica, 2007